Alterity Receives Positive FDA Feedback From Type C Meeting
Filed with ASX · · 3 pages · English
Alterity Therapeutics Ltd. on 6ix
In the deck
Earlier from Alterity Therapeutics
- Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
- Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
- Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
- Half Yearly Report and Accounts
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Later from Alterity Therapeutics
- Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
- Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
- Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
- Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
- Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics